A Study Evaluating Safety, Pharmacokinetics, and Therapeutic Activity of RO6874281 as a Single Agent (Part A) or in Combination With Trastuzumab or Cetuximab (Part B or C)
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Solid Tumor|Breast Cancer|Cancer of Head and Neck
Interventions: DRUG: RO6874281|DRUG: Trastuzumab|DRUG: Cetuximab
Sponsor: Hoffmann-La Roche